Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity

INTRODUCTION: Continuous antiretroviral therapy (ART) suppresses HIV plasma viral load (pVL) to very low levels, which allows for some immune recovery. Discontinuation of ART leads to pVL rebound from reservoirs of persistence and latency, and progressive immunodeficiency. One promising but controve...

Descripción completa

Detalles Bibliográficos
Autores principales: McGuinty, Michaeline, Angel, Jonathan B, Cooper, Curtis L, Cowan, Juthaporn, MacPherson, Paul A, Kumar, Ashok, Murthy, Sanjay, Sy, Richmond, Dennehy, Michelle, Tremblay, Nancy, Byrareddy, Siddappa N, Cameron, D William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
HIV/AIDS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545629/
https://www.ncbi.nlm.nih.gov/pubmed/33033101
http://dx.doi.org/10.1136/bmjopen-2020-041359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545629/
https://www.ncbi.nlm.nih.gov/pubmed/33033101
http://dx.doi.org/10.1136/bmjopen-2020-041359

Ejemplares similares